Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher.
Participant has adequate intravenous infusion access per investigator's judgement
Willing to comply with study procedures including skin punch biopsies procedures.
Weight is greater than 40 kg and less than 130 kg.
You may not be if
Skin disorders other than CLE or SLE.
Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids.
Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.
Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.
Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments.
History of disseminated herpes zoster/simplex or recurrent herpes zoster.
Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline.
Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB)
Clareo Health | A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
